Profile

Business Description

Cocrystal Pharma, Inc. is a clinical stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of hepatitis viruses, influenza viruses, and noroviruses. We employ unique structure-based technologies and Nobel Prize winning expertise to create first- and best-in-class antiviral drugs. The Company is developing CC-31244, an investigational, oral, broad-spectrum replication inhibitor called a non-nucleoside inhibitor (NNI). CC-31244 is currently being evaluated in a Phase 2a study for the treatment of hepatitis C as part of a cocktail for ultra-short therapy of 4 to 6 weeks. Cocrystal recently entered into an exclusive worldwide license and collaboration agreement with Merck & Co., Inc. to discover and develop certain proprietary influenza A/B antiviral agents. CC-42344, the Company’s molecule for the treatment of influenza A, is currently being evaluated in preclinical IND-enabling studies. In addition, the Company has a pipeline of promising early discovery program to identify and develop novel antivirals for the treatment of norovirus gastroenteritis.

Company Info

Address:
19805 N. Creek Parkway
Bothell, WA 98011 US

Telephone:
678-892-8800

Fax:
404-601-1431

Email:
info@cocrystalpharma.com

Industry Classifications

NAICS:
Research and Development in Biotechnology (541711)

SIC:
Commercial Physical and Biological Research (8731)

ICB:
Biotechnology (4573)

GICS:
Pharmaceutical, Biotechnology & Life Sciences (3520)